ReferenceRRK6629
ENHANCE
A 52-week placebo-controlled randomized Phase 3 study to evaluate the safety and efficacy of seladelpar in subjects with primary biliary cholangitis (PBC) and an inadequate response to or an intolerance to ursodeoxycholic acid (UDCA)
Research Summary
Research Overview | |
---|---|
Project Status | Open |
Proposed End Date | 21/11/2020 |
Study Run through CRF? | No |
Target number of patients agreed to recruit | 2 |
Recruitment so far | 0 |